

References

I-58

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/>
2. Doerfler P, Nayak S, Corti M, et al. Targeted approaches to induce immune tolerance for Pompe disease therapy. *Mol Ther Methods Clin Dev.* 2016; 3:15053.
3. Micromedex DrugDex Compendium®. 2021. Alglucosidase alfa.
4. Clinical Pharmacology Compendia. [database online].2021. Tampa FL: Gold Standard, Inc. Alglucosidase alfa.
5. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
6. van der Meijden JC, Kruijshaar ME, Harlaar L, et al. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. *J Inherit Metab Dis.* 2018; 41(6):1205-14.
7. Byrne BJ, Fuller DD, Smith BK, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. *Ann Transl Med.* 2019; 7(13): 290-302.
8. Parini R, De Lorenzo P, Dardis A, et al. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. *Orphanet J Rare Dis.* 2018; 13(1):32.
9. Confalonieri M, Vitacca M, Scala R, et al. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. *Orphanet J Rare Dis.* 2019;14(1):62.
10. Alglucosidase alfa (Lumizyme) for injection, for intravenous use [package insert]. Genzyme Corporation. Cambridge, MA. Revised 02/2021.
11. Avalglucosidase alfa-ngpt (Nexviazyme) for injection, for intravenous use [package insert]. Genzyme Corporation. Cambridge, MA. Issued 08/2021.
12. Clinical Pharmacology™ 2021. Tampa FL: Gold Standard, Inc. Avalglucosidase alfa.
13. Micromedex DrugDex Compendium®. 2021. Avalglucosidase alfa-ngpt.
14. Avalglucosidase Alfa-ngpt In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 30, 2021.
15. Avalglucosidase alfa-ngpt. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.

16. Pena LDM, Barohn RJ, Byrne BJ, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. *Neuromuscul Disord.* 2019;29(3):167-186.